We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00418561
First Posted: January 5, 2007
Last Update Posted: April 27, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Shire
Results First Submitted: July 16, 2015  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Factorial Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Metachromatic Leukodystrophy (MLD)
Intervention: Drug: rhASA

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Cohort 1 Single dose of 25 U/kg recombinant human Arylsulphatase A (Metazym, rhASA), thereafter, received repeated doses of 50 U/kg recombinant human Arylsulphatase A, once in every 2 weeks for a period of 26 weeks, as an intravenous (IV) infusion over 30 minutes. Dosage adjustment was done monthly to account for changes in body weight.
Cohort 2 Repeated doses of 100 U/kg recombinant human Arylsulphatase A (Metazym, rhASA), once in every 2 weeks for a period of 26 weeks, as an IV infusion over 30 minutes. Dosage adjustment was done monthly to account for changes in body weight.
Cohort 3 Repeated doses of 200 U/kg recombinant human Arylsulphatase A (Metazym, rhASA), once in every 2 weeks for a period of 26 weeks, as an IV infusion over 60 minutes. Dosage adjustment was done monthly to account for changes in body weight.

Participant Flow:   Overall Study
    Cohort 1   Cohort 2   Cohort 3
STARTED   4   5   4 
COMPLETED   4   4   4 
NOT COMPLETED   0   1   0 
Participant's (guardian's) decision                0                1                0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat (ITT) population included all participants who received at least 1 dose of study drug.

Reporting Groups
  Description
Cohort 1 Single dose of 25 U/kg recombinant human Arylsulphatase A (Metazym, rhASA), thereafter, received repeated doses of 50 U/kg recombinant human Arylsulphatase A, once in every 2 weeks for a period of 26 weeks, as an IV infusion over 30 minutes. Dosage adjustment was done monthly to account for changes in body weight.
Cohort 2 Repeated doses of 100 U/kg recombinant human Arylsulphatase A (Metazym, rhASA), once in every 2 weeks for a period of 26 weeks, as an IV infusion over 30 minutes. Dosage adjustment was done monthly to account for changes in body weight.
Cohort 3 Repeated doses of 200 U/kg recombinant human Arylsulphatase A (Metazym, rhASA), once in every 2 weeks for a period of 26 weeks, as an IV infusion over 60 minutes. Dosage adjustment was done monthly to account for changes in body weight.
Total Total of all reporting groups

Baseline Measures
   Cohort 1   Cohort 2   Cohort 3   Total 
Overall Participants Analyzed 
[Units: Participants]
 4   5   4   13 
Age 
[Units: Months]
Mean (Standard Deviation)
 36.25  (9.32)   41.80  (10.13)   30.75  (7.27)   36.69  (9.59) 
Gender 
[Units: Participants]
       
Female   2   3   3   8 
Male   2   2   1   5 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Treatment-emergent Adverse Events (TEAEs)   [ Time Frame: From study drug administration up to Week 28 ]

2.  Primary:   Change From Baseline in Gross Motor Function Measure (GMFM) at Week 26   [ Time Frame: Baseline, Week 26 ]

3.  Primary:   Change From Baseline in Cerebrospinal Fluid (CSF) Sulfatide at Week 26   [ Time Frame: Baseline, Week 26 ]

4.  Primary:   Number of Participants With Shift From Baseline to Week 26 in Sulfatide Levels in Urine   [ Time Frame: Baseline up to Week 26 ]

5.  Primary:   Change From Baseline in Mullen’s Scales of Early Learning at Week 26   [ Time Frame: Baseline, Week 26 ]

6.  Primary:   Maximum Plasma Drug Concentration (Cmax) of Recombinant Human Arylsulphatase A (rhASA)   [ Time Frame: Pre-dose and post-dose at 20, 40, 90 minutes, 3, 6 and 8 hours on Day 0, 40 minutes post-dose at Week 4, Pre-dose and post-dose at 20, 40, 90 minutes, 3, 6 and 8 hours at Week 8 ]

7.  Primary:   Arylsulfatase A (ASA) Activity in Leukocytes   [ Time Frame: Pre-dose and post-dose at 24 hours on Day 0 and at Weeks 8 and 26 ]

8.  Secondary:   Change From Baseline in Nerve Conduction Velocity at Week 26   [ Time Frame: Baseline, Week 26 ]

9.  Secondary:   Number of Participants Who Had Undergone Nerve Biopsy and Had a Normal Nerve at Both Baseline and Week 26   [ Time Frame: Baseline, Week 26 ]

10.  Secondary:   Number of Participants With Shift From Baseline to Week 26 in Magnetic Resonance Imaging (MRI)-Loes Scores   [ Time Frame: Baseline up to Week 26 ]

11.  Secondary:   Change From Baseline in Paediatric Evaluation of Disability Inventory (PEDI) Scores at Week 26   [ Time Frame: Baseline, Week 26 ]

12.  Other Pre-specified:   Number of Participants With Shift From Baseline to Week 26 in Clinical Laboratory Evaluations: Biochemistry   [ Time Frame: Baseline up to Week 26 ]

13.  Other Pre-specified:   Number of Participants With Shift From Baseline to Week 26 in Clinical Laboratory Evaluations: Coagulation   [ Time Frame: Baseline up to Week 26 ]

14.  Other Pre-specified:   Number of Participants With Shift From Baseline to Week 26 in Clinical Laboratory Evaluations: Genotyping   [ Time Frame: Baseline up to Week 26 ]

15.  Other Pre-specified:   Number of Participants With Shift From Baseline to Week 26 in Clinical Laboratory Evaluations: Hematology   [ Time Frame: Baseline up to Week 26 ]

16.  Other Pre-specified:   Number of Participants With Abnormal Findings in Urine Analysis   [ Time Frame: Baseline up to Week 26 ]

17.  Other Pre-specified:   Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Findings   [ Time Frame: Baseline up to Week 26 ]

18.  Other Pre-specified:   Change From Baseline in Chitotriosidase at Week 26   [ Time Frame: Baseline, Week 26 ]

19.  Other Pre-specified:   Change From Baseline in Neurofilament Proteins (NFP), Glial Fibrillary Acidic Protein (GFAP) and Tauprotein in Cerebrospinal Fluid (CSF) at Week 26   [ Time Frame: Baseline, Week 26 ]

20.  Other Pre-specified:   Change From Baseline in Amplitude at Week 26   [ Time Frame: Baseline, Week 26 ]

21.  Other Pre-specified:   Physical Examination Results   [ Time Frame: Baseline up to Week 26 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
ASA activity in leukocytes could not be included in basic results format as the results were presented graphically. Due to quick disappearance of rhASA from plasma, rhASA levels were not possible to report.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Study Physician
Organization: Shire
phone: 1866-842-5335



Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT00418561     History of Changes
Other Study ID Numbers: rhASA-01
2006-005341-11 ( EudraCT Number )
First Submitted: January 4, 2007
First Posted: January 5, 2007
Results First Submitted: July 16, 2015
Results First Posted: August 13, 2015
Last Update Posted: April 27, 2016